Allergen immunotherapy in children and adolescents with respiratory diseases

Maria Angela Tosca, Amelia Licari, Roberta Olcese, Riccardo Castagnoli, Alessia Marseglia, Gian Luigi Marseglia, Michele Miraglia Del Giudice, Alberto Martelli, Mauro Calvani, Carlo Caffarelli, Marzia Duse, Claudio Cravidi, Fabio Cardinale, Giorgio Ciprandi

Research output: Contribution to journalReview articlepeer-review


To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. (

Original languageEnglish
Article numbere2020006
Pages (from-to)1-4
Number of pages4
JournalActa Biomedica
Publication statusPublished - 2020


  • Allergen-specific immunotherapy
  • Allergic asthma
  • Children
  • Subcutaneous immunotherapy
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Allergen immunotherapy in children and adolescents with respiratory diseases'. Together they form a unique fingerprint.

Cite this